← Eichor
Condition: Resectable Stage Ii Iii Non Small Cell Lung Cancer Nsclc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Resectable Stage Ii Iii Non Small Cell Lung Cancer Nsclc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Phase 3 · 7 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT04316364IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Phase 2 · 30 location(s) · Innate Pharma · NCT05742607Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06734182A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After R
Phase 2 · 1 location(s) · Zeng Jian · NCT06424899A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of
Phase 2 · 10 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT05913089PALACE: Cemiplimab Trial According to ctDNA Levels
Phase 2 · 20 location(s) · Fundación GECP · NCT06917573A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-s
Phase 3 · 42 location(s) · ETOP IBCSG Partners Foundation · NCT06284317Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage I
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07410975Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
Phase 3 · 2 location(s) · Hunan Province Tumor Hospital · NCT07251582A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cance
Phase 2 · 38 location(s) · Genentech, Inc. · NCT04302025Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-
Phase 3 · 1 location(s) · Shanghai Chest Hospital · NCT06437977Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Si
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT07089199IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage
Phase 2 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07122687
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.